SK Biopharm holds sales meeting for marketing Cenobamate in US

The S.Korean pharmaceutical company will strengthen sales of its epilepsy drug targeting US medical staff and patients

jyhan@hankyung.com

Feb 16, 2023 (Gmt+09:00)

1 Min read

Language selection
Text Size
- T X-Small
- T Small
- T Medium
- T Large
- T X-Large
Share
- Facebook
- Twitter
- Linkedin
- Whatsapp
- Line
- E-mail
Currency Converter
Currency Converter

from

to

News⁺

The Korea Economic Daily App

SK　Biopharm's　sales　meeting　in　San　Diego

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego.

The purpose of the event is to motivate sales organizations and share future visions among US pharmaceutical companies.

Since the release of Cenobamate, an epilepsy treatment, in the United States in 2020, SK Biopharm has held a national sales meeting annually.

The company claims to be the only South Korean drug company to organize such an event.

"This year, we will be able to enhance our potential and achieve sustainable growth by targeting sales towards local medical staff and patients who have not previously used Cenobamate," said Lee Dong-hoon, CEO of SK Biopharmaceuticals.

Write to Jae-Young Han at jyhan@hankyung.com